An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies

Autor: Almas Hanif Mulla, Jonaid Ahmad Malik, Turki Al Hagbani, Saleh Alghamdi, Sirajudheen Anwar, Mohammed Abrar Ubaid, Khaled Almansour, Tahmeena Farooqi
Rok vydání: 2021
Předmět:
Epidemiology
ERGIC
endoplasmic reticulum- golgi intermediate compartment

DMVs
double-membrane vesicles

MVA
modified vaccinia virus Ankara

Disease
IMV
Instruments de Médecine Vétérinaire

RVF
Rift Valley fever

IDIBAPS
Pi i Sunyer Biomedical Research Institute

FiO2
fraction of inspired oxygen

CCHFV
Crimean-Congo hemorrhagic fever virus

LiteVax BV
spike-based (epitope screening)

Medicine
ExoN
exoribonuclease

SpO2
oxygen saturation

CARDS
Covid 19 acute respiratory distress syndrome

Coronavirus
NSP
non-Structural proteins

IEM
Institute For Engineering in Medicine

RBD
receptor-binding domain

SRC VB VECTOR
State Research Centre of Virology and Biotechnology

General Medicine
TRSs
transcriptional regulatory sequences

Variant strains
COVID-19
corona virus disease 2019

VLP
virus like particle

CNRS
centre national de la recherche scientifique

Workforce
ARTES
Germany: based biotechnology company specialized in recombinant protein production and process development from microbial expression systems

CRP
C-reactive protein

LVVV
live viral vectored vaccine

Public aspects of medicine
MIGAL
Galilee Research Institute Ltd

O-MT
O-methyl transferase-2

medicine.medical_specialty
MARV
Marburg virus

USAMRIID/WARIAR
United States Army Medical Research Institute of Infectious

MMR
measles mumps rubella

NiV
Nippa virus

Humans
LLC
low lung compliance

Intensive care medicine
PaCO2
partial pressure of carbon dioxide

VOHC
variant of high consequences

NERVTAG
new and emerging respiratory virus Threats advisory group

OMV
outer membrane vesicle

Osivax
clinical stage biotechnology company

GPO
Government Pharmaceutical Organization

VOC
variant of concern

NLC
nanostructured Lipid Carriers

MDA5
melanoma differentiation associated protein

Public Health
Environmental and Occupational Health

NIV
non-invasive ventilation

medicine.disease
InfA
influenza virus-A

COPD
chronic obstructive pulmonary disease

CPAP
continuous positive airway pressure

VEE
Venezuelan equine encephalitis

SARS-CoV-2
severe acute respiratory syndrome coronavirus-2

CBC
complete blood count

ADRP
ADP ribose-1′-phosphatase

CNBG
China National Biotec Group

INRAE
National Research Institute for Agriculture
Food and Environment

CHIKV
chikungunya virus

PEEP
positive end-expiratory pressure

Infectious and parasitic diseases
RC109-216
RTC
replication transcription complex

medicine.disease_cause
WHO landscape
CDC
center for disease control and prevention

PaO2
partial pressure of oxygen

VOI
variant of interest

IAVI
international AIDS vaccine initiative

GCIR
German Center for Infection Research

Vaccines
SIG
SARS-COV-2 Interagency Group

MERS-CoV
Middle East Respiratory Syndrome coronavirus

CanVirex AG
Swiss Biotech Association

Vaccine candidates
LinKinVax
French biotechnology startup that focuses on speeding up vaccine

Infectious Diseases
Original Article
EBOV
Ebola virus

RA1-1270
GMV
glycine mosaic virus

IPV
inactivated polio virus

COVID-19 Vaccines
VSV
vesicular stomatitis virus

Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
SARS-COV-2
ORFs
open reading frames

LASSA
lassa virus

P.C.
preclinical

ACE2
angiotensin-converting enzyme-2

RdRp
RNA dependent RNA polymerase

VRI
Vaccine Research Institute

TMPRSS2
transmembrane protein serine 2

NSCLC
non-small cell lung cancer

ECDC
European Centre for Disease Prevention and Control

HeV
hepatitis virus E

GLA
glucopyranosyl Lipid A

LASV
lassa mammarenavirus

DWRAIR
Diseases/Walter Reed Army Institute of Research

DZIF
German Center for Infection Research

business.industry
COVID-19
HLC
high lung compliance

PPI
proton pump inhibitors

CMV
cytomegalovirus

Vaccine efficacy
RTI
respiratory tract infections

HBV
hepatitis B virus

NORV
norovirus

HFNC
high-flow nasal cannula

Middle East respiratory syndrome
CEA
carcinoembryonic antigen

business
BIOCAD
BIO computer aided design RNA
Zdroj: Journal of Infection and Public Health
Journal of Infection and Public Health, Vol 14, Iss 10, Pp 1299-1312 (2021)
ISSN: 1876-0341
DOI: 10.1016/j.jiph.2021.08.014
Popis: Background: Over the last two decades, humanity has observed the extraordinary anomaly caused by novel, weird coronavirus strains, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). As the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has made its entry into the world, it has dramatically affected life in every domain by continuously producing new variants. The vaccine development is an ongoing process, although some vaccines got marketed. The big challenge is now whether the vaccine candidates can provide long-lasting protection or prevention against mutant variants. Methods: The information was gathered from various journals, electronic searches via Internet-based information such as PubMed, Google Scholar, Science Direct, online electronic journals, WHO landscape, world meters, WHO website, and News. Results: This review will present and discuss some coronavirus disease 19 (COVID-19) related aspects including: the pathophysiology, epidemiology, mutant variants vaccine candidates, vaccine efficacy, and management strategies. Due to the high death rate, continuous spread, an inadequate workforce, lack of required therapeutics, and incomplete understanding of the viral strain, it becomes crucial to build the knowledge of its biological characteristics and make available the rapid diagnostic and vital therapeutic machinery for the combat and management of an infection. Conclusion: The data summarizes current research on the COVID 19 infection and therapeutic interventions, which will direct future decision-making on the effort-worthy phases of the COVID 19 and the development of critical therapeutics. The only possible solution is the vaccine development targeting against all variant strains to halt its progress; the identified theoretical and practical knowledge can eliminate the gaps to improve a better understanding of the novel coronavirus structure and its design of a vaccine. In addition, to that the long-lasting protection is another challenging objective that need to be looked into.
Databáze: OpenAIRE